- $466.00m
- $308.25m
- $65.44m
- 43
- 25
- 41
- 28
Annual income statement for Ceribell, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 25.9 | 45.2 | 65.4 |
| Cost of Revenue | |||
| Gross Profit | 21.5 | 38.2 | 56.8 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Total Operating Expenses | 61.9 | 75.3 | 105 |
| Operating Profit | -36 | -30 | -39.7 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -37.2 | -29.5 | -40.5 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -37.2 | -29.5 | -40.5 |
| Net Income Before Extraordinary Items | |||
| Net Income | -37.2 | -29.5 | -40.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -37.2 | -29.5 | -40.5 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -1.09 | -0.866 | -1.13 |